Molecules May ID at-Risk Leukemia Patients
Posted on: Wednesday, 16 January 2008, 15:00 CST
U.S. medical scientists have determined certain molecules used by cells to control proteins might help physicians identify high-risk leukemia patients.
The Ohio State University researchers said the small microRNA molecules make might make it possible to identify adult acute-leukemia patients who are likely to respond poorly to therapy.
The scientists examined the levels of microRNAs in leukemia cells from 122 patients with high- and intermediate-risk AML and in normal blood stem cells from 10 healthy donors.
The findings showed both the leukemia and the normal cells had similar kinds of microRNA, but the two groups differed in the levels of microRNAs present. The research also identified two microRNAs present at abnormally high levels that were clearly associated with patient survival.
If our results are validated by other groups, these two elevated microRNAs can be used to determine which patients require more aggressive treatment, said Dr. Ramiro Garzon. In addition, they may provide new targets for future therapies -- knocking out these two microRNAs might benefit patients who have a poor prognosis.
The study appears in the online issue of the journal Blood.
Source: United Press International
Related Articles
- Study: Physical Therapists Can Reduce Disability And Improve Function In Patients Who Have Undergone Single-Level Microdiskectomy
- Liver Cells Grown From Patients' Skin Cells
- Cyclacel Reports Phase I Sapacitabine Data in Patients With Advanced Leukemias and Myelodysplastic Syndromes at 2007 ASCO Annual Meeting
- Cyclacel Reports Interim Phase I Data for Sapacitabine in Patients With Advanced Leukemias or Myelodysplastic Syndromes
- BioCryst Receives Special Protocol Assessment (SPA) From FDA for Pivotal Trial of Fodosine(TM) in T-Cell Leukemia
- Cyclacel Begins Phase I Pharmacologic Study of Oral Sapacitabine in Patients With Advanced Leukemias
- BioCryst Initiates Intravenous Phase I/II Clinical Trial of Fodosine(TM) in Patients With B-Cell Acute Lymphoblastic Leukemia
- BioCryst Announces Filing of Special Protocol Assessment for Fodosine(TM) in the Treatment of Relapsed or Refractory T-Cell Leukemia
- Transgenomic's WAVE(R) System and Surveyor(TM) Nuclease Used for Detection and Monitoring of Low-Level Mutation in Mast Cell Leukemia
- BioCryst Receives FDA Fast Track Status for Fodosine(TM) in the Treatment of Relapsed or Refractory T-Cell Leukemia
 |
 |
User Comments (0)
RSS Feeds